The main market opportunities in the eosinophilic esophagitis pipeline include focusing on novel therapeutic approaches, potential development of first-in-class treatments like IRL201104, targeting ...
Twelve fecal metabolites are significantly altered among patients with irritable bowel syndrome compared with healthy control individuals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback